Preliminary data from Ph 2 MRD translational clinical trial of IMNN-001 + SOC N/ACT & bevacizumab in women with 1L advanced ovarian cancer announced
“We are encouraged by these new data points from our MRD study, which continue to build the case for IMNN-001’s potential to make a meaningful difference for women with newly diagnosed advanced ovarian cancer,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “These findings, together with the consistent safety profile we’ve now observed across multiple studies, reinforce that we have overcome the historical safety and efficacy barriers associated with the development of a novel IL-12 immunotherapy and further bolster our confidence in IMNN-001 as we continue to advance our pivotal Phase 3 OVATION 3 trial.”
Share:
More News
“With this financing, we are well positioned to complete IND-enabling studies and advance TAVST01 toward its planned IND submission, bringing us closer to delivering a scalable, readily available, and potentially transformative cell therapy for patients with solid tumors”, said Dr. Ivan Horak, Founder and Chief Executive Officer of Tikva Allocell.
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” said Vinita Gupta, Chief Executive Officer, Lupin. “The strength of these assets, combined with Kaveri’s seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of
Dr Jonathan Kwok, Co-Founder, President and Chief Medical Officer, Infinitopes, said, “Entering the clinic is a defining milestone for successful future medicines. For Infinitopes, VISTA represents the first clinical evaluation of our integrated approach that combines Precision Immunomics target discovery with proven viral vectors, to engineer precise, off-the-shelf therapies for